Clinical studies have shown that immune checkpoint LAG-3 has not been found to be correlated with cardiac complications like atherosclerosis, and coronary heart disease, because of which the FDA has approved them for anti-tumor therapy. This evidence concerns the gene LAG3 and coronary artery disorder.